Neopharmed Gentili S.p.A. (“Neopharmed”), an Italian pharmaceutical company active in the marketing of high-value therapeutic solutions, controlled by the Del Bono Family and two leading international private equity firms, Ardian and Renaissance Partners, today announced that it has entered into an exclusive licensing agreement with global pharma major Lupin Limited (“Lupin”) for the commercialization and promotion of its leading gastroenterology brand Plasil^® (metoclopramide) in Brazil and the Philippines.